PFIZER INC (PFE) Latest Company News

Jul 2, 2026, 17:51 UTC
Knoa Pharma appointed Michael Goettler as its CEO and president.
Source:
- nhregister.com
Jun 29, 2026, 05:20 UTC
Pfizer's Ecnoglutide and Innovent Biologics' mazdutide injection passed a preliminary review by China's National Healthcare Security Administration for potential inclusion in the basic medical insurance drug catalogue.
Source:
- reuters.com
Jun 24, 2026, 19:52 UTC
Pfizer's board of directors declared a $0.43 per share quarterly cash dividend for the third quarter of 2026, payable on September 1, 2026, to shareholders of record on July 24, 2026.
Source:
- businesswire.com
Jun 24, 2026, 18:10 UTC
The U.S. FDA approved Pfizer's IBRANCE regimen for maintenance treatment of HR+, HER2+ metastatic breast cancer.
Source:
- businesswire.com
Jun 24, 2026, 15:30 UTC
Pfizer was dismissed as a defendant in a US states' antitrust lawsuit alleging generic drug price-fixing.
Source:
Jun 23, 2026, 00:00 UTC
Avalo Therapeutics appointed Ron Philip as a director, effective June 23, 2026.
Jun 22, 2026, 21:36 UTC
Pfizer's experimental lung cancer drug sigvotatug vedotin failed to meet its endpoint in a clinical trial.
Source:
- statnews.com
- reuters.com
Jun 17, 2026, 00:00 UTC
Rigel Pharmaceuticals completed the acquisition of exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) from Arvinas entities and Pfizer.
Source:
Jun 9, 2026, 15:56 UTC
Pfizer received FDA approval to expand the use of its hemophilia drug Hympavzi to additional patient groups, including children with inhibitors.
Source:
- zacks.com
Jun 8, 2026, 11:04 UTC
Pfizer reported positive mid-stage trial data for berobenatide, a GLP-1 obesity therapy with monthly dosing, and plans up to 10 Phase 3 trials for long-term obesity management and related conditions.
Source:
- seekingalpha.com
Jun 8, 2026, 10:45 UTC
The U.S. FDA approved an expanded indication for Pfizer's HYMPAVZI to treat additional hemophilia A or B patient populations.
Source:
- businesswire.com
- reuters.com
Jun 6, 2026, 13:06 UTC
Pfizer presented data on Saturday showing that a monthly dose of an experimental obesity drug acquired through its purchase of Metsera last year had a similar side-effect profile as Novo Nordisk's Wegovy.
Source:
- reuters.com

← PreviousPage 3

PFE

Knoa Pharma appointed Michael Goettler as its CEO and president.

Pfizer's Ecnoglutide and Innovent Biologics' mazdutide injection passed a preliminary review by China's National Healthcare Security Administration for potential inclusion in the basic medical insurance drug catalogue.

Pfizer's board of directors declared a $0.43 per share quarterly cash dividend for the third quarter of 2026, payable on September 1, 2026, to shareholders of record on July 24, 2026.

The U.S. FDA approved Pfizer's IBRANCE regimen for maintenance treatment of HR+, HER2+ metastatic breast cancer.

Pfizer was dismissed as a defendant in a US states' antitrust lawsuit alleging generic drug price-fixing.

Avalo Therapeutics appointed Ron Philip as a director, effective June 23, 2026.

Pfizer's experimental lung cancer drug sigvotatug vedotin failed to meet its endpoint in a clinical trial.

Rigel Pharmaceuticals completed the acquisition of exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) from Arvinas entities and Pfizer.

Pfizer received FDA approval to expand the use of its hemophilia drug Hympavzi to additional patient groups, including children with inhibitors.

Pfizer reported positive mid-stage trial data for berobenatide, a GLP-1 obesity therapy with monthly dosing, and plans up to 10 Phase 3 trials for long-term obesity management and related conditions.

The U.S. FDA approved an expanded indication for Pfizer's HYMPAVZI to treat additional hemophilia A or B patient populations.

Pfizer presented data on Saturday showing that a monthly dose of an experimental obesity drug acquired through its purchase of Metsera last year had a similar side-effect profile as Novo Nordisk's Wegovy.